Table 5. Comparisons between serum... | American Society of Hematology

Table 5.

Comparisons between serum levels of hematopoietic growth factors of HCV-negative HD patients with and without rhEPO replacement therapy

Subjects	Age (y)	HD duration (y)	Platelet counts (×10⁹/L)	Hct (%)	TPO (pg/mL)	EPO (mU/mL)
HD patients with rhEPO (n = 33)	55.9 ± 12.1	12.2 ± 5.90	189.4 ± 58.0	30.2 ± 2.96	95.1 ± 35.5	17.7 ± 7.65
HD patients without rhEPO (n = 33)	56.2 ± 9.40	14.6 ± 6.29	189.2 ± 49.2	34.9^5-150 ± 3.29	120.3^5-151 ± 48.2	17.8 ± 12.3

Subjects	Age (y)	HD duration (y)	Platelet counts (×10⁹/L)	Hct (%)	TPO (pg/mL)	EPO (mU/mL)
HD patients with rhEPO (n = 33)	55.9 ± 12.1	12.2 ± 5.90	189.4 ± 58.0	30.2 ± 2.96	95.1 ± 35.5	17.7 ± 7.65
HD patients without rhEPO (n = 33)	56.2 ± 9.40	14.6 ± 6.29	189.2 ± 49.2	34.9^5-150 ± 3.29	120.3^5-151 ± 48.2	17.8 ± 12.3

P < .01 vs HD patients with rhEPO;

P < .02 vs HD patients with rhEPO.

Data are shown as the mean ± SD.

Hct, hematocrits; TPO, thrombopoietin; EPO, erythropoietin.

All experiments were conducted in duplicate.